Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Hallal David  (First) (Middle)						2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC ALXN									Director Officer below)	,		10% Ov Other (s below)	vner specify	
C/O ALEXION PHARMACEUTICALS, INC 352 KNOTTER DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 07/27/2012								C Indi	SVP. Global Commercial Ops					
(Street) CHESHIRE CT 06410 (City) (State) (Zip)				_   4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								b. Indi Line) X	vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person						
(1.9)				on-Deri	vativ	e Se	curit	ties Ac	quire	d, Di	isposed o	of, or Be	nefic	ially	Owned					
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/					Execution Date			3. Transa Code (I 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a			5. Amou Securitie Benefici Owned I		es ally Following	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		Reported Transact (Instr. 3	tion(s)			(Instr. 4)	
Common Stock, par value \$.0001 per share 07/27/20					2012	12			M		50,000	A	\$17	17.65 113		3,210	D			
Common Stock, par value \$.0001 per share 07/27/20					2012	012			S		50,000	D	\$107	)7.74 <sup>(1)</sup> 63,		210		D		
Common Stock, par value \$.0001 per share 07/27/20					2012	012			S		555(2)	D	\$10	5106.14 62		,655		D		
Common Stock, par value \$.0001 per share 07/31/20					2012	)12			S		680(2)	D	\$104	5104.99		,975		D		
			Table II								posed of, converti				wned			,		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Execution if any (Month/	on Date,	4. Transa Code ( 8)				6. Date Exerc Expiration Da (Month/Day/Y		ate	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ity (I	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	i C F ily D o (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amou or Numb of Share	oer						
Option to Purchase Common	\$17.65	07/27/2012			M			50,000	04/09/2	2008	01/09/2018	Common Stock, par value \$ 0001	50,0	00	<b>\$</b> 0	64,33	6	D		

## **Explanation of Responses:**

Stock

- 1. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$107.00 \$107.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- 2. These sales were made to cover the withholding taxes immediately following the vesting of previously granted Restricted Stock.

/s/ David Hallal

per share

07/31/2012

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.